Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Rhea-AI Summary

Iovance Biotherapeutics (NASDAQ: IOVA) will report fourth quarter and full year 2025 financial results and provide corporate updates via a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET.

According to the company, the live and archived webcast will be available on the Investors section of its website and the archived webcast will remain accessible for one year.

Key Figures

Earnings call date: February 24, 2026 Earnings call time: 8:30 a.m. ET Webcast archive duration: 1 year

3 metrics

Earnings call date February 24, 2026 Scheduled fourth quarter and full year 2025 results

Earnings call time 8:30 a.m. ET Start time of conference call and webcast

Webcast archive duration 1 year Archived webcast availability period

Market Reality Check

Price: $2.59 Vol: Volume 6,193,582 is below...

low vol

$2.59 Last Close

Volume Volume 6,193,582 is below the 20-day average of 12,201,771 ahead of the earnings call announcement. low

Technical Shares at $2.60 are trading above the 200-day MA of $2.34, but remain 57.31% below the 52-week high of $6.09.

Peers on Argus

IOVA showed no price change, while close biotech peers were mixed: NKTR up 18.77...

IOVA showed no price change, while close biotech peers were mixed: NKTR up 18.77%, IMNM up 1.01%, and SANA, EYPT, URGN down between 1–4%, suggesting stock-specific rather than sector-driven dynamics.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Clinical data update	Positive	-3.3%	Real‑world Amtagvi data showing strong response and disease control rates.
Jan 16	Inducement grants	Neutral	+3.4%	Stock option inducement grants to new non‑executive employees.
Dec 19	Inducement grants	Neutral	+12.1%	Additional option grants to new employees under inducement plan.
Nov 21	Inducement grants	Neutral	+11.6%	Larger batch of inducement stock options for new hires.
Nov 06	Earnings and update	Positive	+27.6%	Q3 2025 results with growing product revenue and reaffirmed guidance.

Pattern Detected

Recent history shows mostly aligned reactions, with strong positive moves on favorable earnings and routine equity updates, but one instance where positive clinical data was followed by a negative price reaction.

Recent Company History

Over the last several months, Iovance has balanced commercial, clinical, and corporate developments. A Q3 2025 update with growing revenue and guidance reaffirmation saw a strong positive reaction. Multiple inducement option grants in Nov–Dec 2025 drew modest to solid gains, indicating comfort with routine equity compensation. In contrast, encouraging real‑world Amtagvi data on Feb 5, 2026 coincided with a price decline, showing that positive clinical news has not always translated into immediate upside. Today’s earnings date announcement fits into this cadence of scheduled updates.

Market Pulse Summary

This announcement sets the timing for Iovance’s fourth quarter and full year 2025 results and corpor...

Analysis

This announcement sets the timing for Iovance’s fourth quarter and full year 2025 results and corporate update on February 24, 2026. Recent history includes solid Q3 revenue growth and reaffirmed guidance, alongside important clinical data for Amtagvi. Investors following this event may focus on how full‑year figures compare with prior guidance, updates on cash and operating trends from recent filings, and any new information on commercialization or pipeline timelines shared during the call.

Key Terms

tumor infiltrating lymphocyte (TIL)

1 terms

tumor infiltrating lymphocyte (TIL) medical

"delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients"

Tumor infiltrating lymphocytes (TIL) are immune cells that have left the bloodstream and moved into a tumor, where they recognize and may attack cancer cells; think of them as soldiers that have found the enemy inside a fortress. Their presence can show whether the body’s immune system is already responding to a cancer and TIL can be grown and reintroduced as a personalized cell therapy. For investors, TIL levels and therapies matter because they can predict treatment success, drive clinical trial outcomes, and create commercial or regulatory value in oncology drug and biotech pipelines.

AI-generated analysis. Not financial advice.

SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates.

To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/5rbo34au. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year. 

About Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi^® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi ^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com 
650-260-7120 ext. 150

FAQ

When will Iovance (IOVA) report Q4 and full year 2025 results?

Iovance will report on Tuesday, February 24, 2026 at 8:30 a.m. ET. According to the company, the announcement will be delivered via a conference call and live audio webcast for investors and the public to access.

How can I listen to the Iovance (IOVA) February 24, 2026 webcast?

You can listen via live audio webcast by registering at the provided webcast link or visiting the Investors section of the company website. According to the company, registration is required for live access and archived playback.

Will the Iovance (IOVA) webcast be available after the live call?

Yes, the webcast will be archived and available for replay for one year. According to the company, the archived audio webcast can be accessed in the Investors section of the company website for up to twelve months after the live event.

What topics will Iovance (IOVA) cover in the February 24, 2026 call?

The company will report fourth quarter and full year 2025 financial results and provide corporate updates. According to the company, the call is intended to present results and discuss recent corporate developments relevant to investors.

Where is the Iovance (IOVA) webcast archived for investor access?

The archived webcast will be available in the Investors section of the company website, IR.Iovance.com. According to the company, both live and archived audio will be hosted there and accessible after registration.

Is prior registration required to access the Iovance (IOVA) live webcast?

Yes, the company asks listeners to register to access the live audio webcast via the provided registration link. According to the company, registration enables access to the live event and subsequent archived audio.